Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LNA043 · 3 trials · 3 indications
Collagen fibril organization in articular cartilage evaluated by Magnetic Resonance Imaging (MRI) from the cartilage mean T2 relaxation time (with lower values indicative of higher quality). The area of interest is the focal cartilage lesion.
Collagen fibril organization in articular cartilage evaluated by MRI from the cartilage mean T2 relaxation time (with lower values indicative of higher quality). The area of interest is the focal cartilage lesion.
Collagen fibril organization in articular cartilage evaluated by MRI from the cartilage mean T2 relaxation time (with lower values indicative of higher quality).The area of interest is the focal cartilage lesion.
MRI based quantitative assessment using an automated segmentation algorithm
MRI based quantitative assessment using an automated segmentation algorithm.
Treatment emergent other and serious adverse events (TEAE and TESAE) period: Part A: Baseline up to Day 50 (included 30 day safety follow-up Part B: Baseline up to Day 113 (included 30 day safety follow-up) Long term Follow-UP period: Part A: Day 51 to Day 365 Part B: Day 114 to Day 365
To assess the safety and tolerability of single intra-articular injection of LNA043 in Japanese participants with osteoarthritis of the knee
Safety and tolerability of LNA043 after one intra-articular injection into the knee of osteoarthritis patients scheduled for total knee replacement
| Arm | Type | Description |
|---|---|---|
| LNA043 40 mg Part B | EXPERIMENTAL | LNA043 40 mg Part B |
| LNA043 20 mg Part B | EXPERIMENTAL | LNA043 20 mg Part B |
| LNA043 20 mg Part A | EXPERIMENTAL | LNA043 20 mg Part A |
| Placebo Part A | PLACEBO_COMPARATOR | Placebo Part A |
| Placebo Part B | PLACEBO_COMPARATOR | Placebo Part B |
| LNA043 | EXPERIMENTAL | LNA043 |
| placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| LNA043 | BIOLOGICAL | LNA043 intra-articular injection |
| Placebo | OTHER | Placebo intra-articular injection |
Inclusion criteria Part A * Patient was ≥18 and ≤55 years old at time of screening. * Patient had a body mass index (BMI) \<30 kg/m2 at screening, * Patient had a symptomatic, single, articular cartilage defect of one knee, grade II or IIIA according to the ICRS classification, localized to either ...
Top 5 of 14 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, Eloralintide, LY3016859, LY3556050, LY3526318 |
| Pacira Biosciences, Inc. | PCRX | 4 | PHASE3 | ZILRETTA, Enekinragene Inzadenovec, FX201 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 2 | PHASE3 | NNC0487-0111 |
| Bioventus, Inc. Class A | BVS | 1 | PHASE2 | PTP-001 |
| Enlivex Ltd. | ENLV | 2 | PHASE1 | Allocetra |
LNA043 is an investigational small molecule being developed for osteoarthritis, including primary osteoarthritis in patients scheduled for total knee replacement surgery and articular cartilage lesions with knee osteoarthritis. It is administered via intra-articular injection and is currently in clinical development, not yet approved.
LNA043 is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. Novartis is conducting clinical trials to evaluate the safety, tolerability, and preliminary efficacy of LNA043 in patients with osteoarthritis.
LNA043 has completed Phase 2 clinical trials for osteoarthritis. It remains investigational and is not FDA approved. The drug has completed two trials, including a Phase 2 study, and is no longer in active clinical development according to available trial records.
LNA043 has been studied in three completed clinical trials. NCT02491281 was a Phase 1 first-in-human single ascending dose study in patients scheduled for total knee replacement. NCT03275064 was a Phase 2 study of intra-articular injections in patients with articular cartilage lesions and knee osteoarthritis. NCT04564053 was a Phase 1 study in Japanese participants with knee osteoarthritis.
No alternative names for LNA043 have been reported. The drug is identified solely by its code name LNA043 in clinical trial registries and development programs. It is a distinct investigational compound being developed by Novartis for osteoarthritis.